NANO MRNA Seeks Ethics Approval for Phase 1 Trial of Knee Osteoarthritis Drug

MT Newswires Live
08 Jul

NANO MRNA (TYO:4571) said its Australian unit, PrimRNA AU, has submitted a Phase 1 clinical trial plan for its mRNA-based osteoarthritis drug RUNX1 mRNA to the Human Research Ethics Committees, according to a Tuesday filing on the Tokyo Stock Exchange.

The trial targets patients with severe knee osteoarthritis undergoing joint replacement surgery and will assess safety, tolerability, and biomarker expression following intra-articular administration.

Approval from the committee is expected in about six weeks, with trial initiation to follow.

RUNX1 mRNA encodes a transcription factor that promotes cartilage regeneration, aiming to modify the disease rather than just relieve pain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10